CD30.CAR-EBVST cell therapy (Baylor College of Medicine)

N/A

Report date: 2024/07/18 14:49:23

Base Information

Drug NameCD30.CAR-EBVST cell therapy (Baylor College of Medicine)
Drug Alias NameTT-11X
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, Extranodal NK-T-CellLymphoma, Large B-Cell, DiffuseHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of MedicineTessa Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteBaylor College Of MedicineTessa Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Extranodal NK-T-CellLymphoma, Large B-Cell, DiffuseHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A